Health Industry Manufacturers Association
This article was originally published in The Gray Sheet
Executive SummaryBeckman Coulter Chairman, President and CEO John Wareham is elected 2000-2001 HIMA chairman at the association's March 23-24 annual meeting in Tucson, Arizona. A HIMA board member since 1995, and an alumnus of the board's Technology and Regulatory Affairs Policy and In Vitro Diagnostics Sector Advisory Committees, Wareham succeeds Guidant CEO Ronald Dollens in the post
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.